MTA-SZTE Research Group on Artificial Intelligence
SZTE Publicatio Repozitórium - SZTE - Repository of PublicationsNot a member yet
32192 research outputs found
Sort by
Elements of Sustainability in Hungarian Beekeeping Books in the Second Half of the Long 19th Century
Full text linkFunctionalized albumin nanoparticles: A multifunctional platform for enhanced brain drug delivery
Full text link
A menekültügy narratívái az első,a második és a „rózsaszín” nyilvánosságban (1988–1989)
Full text linkTakagi–Sugeno–Kang Fuzzy Inference Tracking Controller for UAV Bicopter
Full text linkThe UAV bicopter is a double-propeller system whose main objective is to stabilize a rod at a given angle by precisely controlling the rotation speed of each propeller. This mechanism generates asymmetric thrust forces that induce a torque on the bar, thus allowing its pitch angle to be modified. Since its dynamics involve complex interactions between the thrust generated by the rotors, aerodynamic effects, and the pendulum behavior of the system, the bicopter is classified as a highly nonlinear system sensitive to external disturbances. To address this complexity, the implementation of a fuzzy Takagi–Sugeno–Kang (TSK) controller is proposed. This controller decomposes the nonlinear dynamics into multiple local linear models associated with a specific operating condition, such as different pitch angles and rotor speeds. The control strategy provides accurate trajectory tracking and effectively handles disturbances and varying conditions, making this approach a practical solution for both dynamic and uncertain environments. This strategy ensures precise trajectory tracking and demonstrates robust performance compared to other control methods, such as PID and LQR, which often struggle with disturbances and system nonlinearities. The TSK controller has proven its effectiveness in experimental trajectory tracking tests, achieving root mean square errors (RMSEs) of 0.2049, 0.3269, 0.3899, 0.3335, and 0.2494, which evaluate the average error in degrees of the system concerning the target position, for tracking trajectories of −10 to 10, −12 to 12, −15 to 15, −17 to 17, and −20 to 20 degrees, respectively
Europeanisation of private international law: Balancing national traditions and EU rules
Full text linkIntravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema : 48-week subgroup analysis of the PHOTON trial
Full text linkIn the pivotal PHOTON trial of patients with diabetic macular edema (DME), aflibercept 8 mg administered every 12 (8q12) and 16 (8q16) weeks demonstrated similar visual and anatomic outcomes with no new safety signals to aflibercept 2 mg every 8 weeks (2q8). We conducted a prespecified subgroup analysis to assess the efficacy, durability, and safety of aflibercept 8 mg in the Japanese patients from PHOTON.Prespecified subgroup analysis of the Phase 3 PHOTON trial (NCT04429503).Adult patients with DME were randomized 1:2:1 to receive intravitreal aflibercept 2q8, 8q12, or 8q16 following initial monthly doses. Patients randomized to 8q12 and 8q16 were eligible for dose regimen modification. The primary endpoint was change from baseline in best-corrected visual acuity (BCVA) at Week 48. Prespecified efficacy and safety outcomes at/through Week 48 are reported, segmented by Japan versus the rest of world (non-Japan).In the Japan and non-Japan subgroups, respectively, mean changes in BCVA were +7.0 and +9.0 (8q12), +7.4 and +7.9 (8q16), and +8.0 and +9.4 (2q8) letters at Week 48; differences in least squares means were -0.30 and -0.64 letters between 8q12 and 2q8 and +0.17 and -1.76 letters between 8q16 and 2q8; ocular treatment-emergent adverse events were reported in 32.4% and 31.6% (8q12), 35.3% and 28.8% (8q16), and 30.0% and 27.2% (2q8) of patients.Improvements in BCVA at Week 48 were generally similar with aflibercept 8 mg versus 2 mg in this subgroup analysis of Japanese and non-Japanese patients with DME, suggesting that the primary findings from PHOTON may be generalized to the Japanese population
Estimating Dynamic Plantar Pressure Distribution from Wearable Inertial Sensors Using a Hybrid CNN-BiLSTM Architecture
Full text linkEfficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
Full text linkAldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension.In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more in a 1:1:1 ratio to receive baxdrostat at a dose of 1 mg, baxdrostat at a dose of 2 mg, or placebo once daily for 12 weeks. The primary end point was the change in seated systolic blood pressure from baseline to week 12.A total of 796 patients underwent randomization and 794 received 1-mg baxdrostat (264 patients), 2-mg baxdrostat (266 patients), or placebo (264 patients) in addition to background therapy. At 12 weeks, the change from baseline in the least-squares mean seated systolic blood pressure was -14.5 mm Hg (95% confidence interval [CI], -16.5 to -12.5) with 1-mg baxdrostat, -15.7 mm Hg (95% CI, -17.6 to -13.7) with 2-mg baxdrostat, and -5.8 mm Hg (95% CI, -7.9 to -3.8) with placebo. The estimated difference from placebo (placebo-corrected difference) was -8.7 mm Hg (95% CI, -11.5 to -5.8) with 1-mg baxdrostat and -9.8 mm Hg (95% CI, -12.6 to -7.0) with 2-mg baxdrostat (P<0.001 for both comparisons). A potassium level of more than 6.0 mmol per liter was reported in 6 patients (2.3%) with 1-mg baxdrostat, in 8 patients (3.0%) with 2-mg baxdrostat, and in 1 patient (0.4%) with placebo.Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo. (Funded by AstraZeneca and others; BaxHTN ClinicalTrials.gov number, NCT06034743.)